Aquestive Therapeutics AQST

Jump To Section

    $

    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    .
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    +$0.02 (+0.65%)Past DayToday's Volume:
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    ,
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    ,
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0

    Relative Strength Index (RSI)

    - The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.

    - The RSI is calculated using the following formula:

    RSI = 100 - (100 / (1 + RS))

    Where RS is the ratio of the average gains to the average losses over a specified period.

    - The default time period used is 14 days.

    - RSI values range between 0 and 100.

    RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)

    RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)

    RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.

    About

    Business overview of Aquestive Therapeutics (AQST)
    Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.

    Key Insights

    Critical company metrics and information

    • Latest Closing Price

      $2.65

    • Market Cap

      $262.01 Million

    • Price-Earnings Ratio

      -5.20

    • Total Outstanding Shares

      98.87 Million Shares

    • Total Employees

      135

    • Dividend

      No dividend

    • IPO Date

      July 25, 2018

    • SIC Description

      Pharmaceutical Preparations

    • Primary Exchange

      NASDAQ

    • Type

      Common Stock

    • Headquarters

      30 technology drive, Warren, NJ, 07059

    • Homepage

      https://www.aquestive.com

    Historical Stock Splits

    Execution DateSplit Amount
    No Historical Stock Splits

    Cash Flow Statement

    January 1, 2024 to December 31, 2024
    MetricValue
    Net Cash Flow$47.67 Million
    Net Cash Flow From Investing Activities$-159,000
    Net Cash Flow, Continuing$47.67 Million
    Net Cash Flow From Operating Activities$-35.76 Million
    Net Cash Flow From Operating Activities, Continuing$-35.76 Million
    Net Cash Flow From Financing Activities, Continuing$83.59 Million

    Income Statement

    January 1, 2024 to December 31, 2024
    MetricValue
    Income Tax Expense/Benefit, Current$-14,000
    Preferred Stock Dividends And Other Adjustments$0
    Income Tax Expense/Benefit, Deferred$0
    Revenues$57.56 Million
    Gross Profit$39.69 Million
    Benefits Costs and Expenses$101.71 Million

    Comprehensive Income

    January 1, 2024 to December 31, 2024
    MetricValue
    Other Comprehensive Income/Loss$-44.14 Million
    Comprehensive Income/Loss Attributable To Noncontrolling Interest$0
    Comprehensive Income/Loss$-44.14 Million
    Comprehensive Income/Loss Attributable To Parent$-44.14 Million

    Balance Sheet

    January 1, 2024 to December 31, 2024
    MetricValue
    Equity$-60.16 Million
    Accounts Receivable$7.34 Million
    Other Current Liabilities$3.85 Million
    Fixed Assets$3.80 Million
    Wages$4.73 Million
    Long-term Debt$45 Million

    Historical Dividends

    Announcement DatePayment DateRecord DateAmountFrequency
    No historical dividends

    Recent Headlines From The Web

    Latest news, press releases, and media coverage about AQST from trusted financial sources
      Boost your savings and earn 4.15% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
      All TickersEarnings CalendarNews ArticlesAbout UsPrivacy & Cookies Info

      ⓒ 2025 Financhle. All Rights Reserved.